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SPECIAL REPORT
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ABSTRACT
Introduction: Although in some countries, palliative care (PC) still remains poorly implemented, its 
importance throughout the course of Parkinson’s disease (PD) is increasingly being acknowledged. With 
an emergence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic, growing 
emphasis has been placed on the palliative needs of people with Parkinson’s (PwP), particularly elderly, 
frail, and with comorbidities.
Areas covered: The ongoing COVID-19 pandemic poses an enormous challenge on aspects of daily 
living in PwP and might interact negatively with a range of motor and non-motor symptoms (NMS), 
both directly and indirectly – as a consequence of pandemic-related social and health care restrictions. 
Here, the authors outline some of the motor and NMS relevant to PC, and propose a pragmatic and 
rapidly deployable, consensus-based PC approach for PwP during the ongoing COVID-19 pandemic, 
potentially relevant also for future pandemics.
Expert opinion: The ongoing COVID-19 pandemic poses a considerable impact on PwP and their 
caregivers, ranging from mental health issues to worsening of physical symptoms – both in the short- 
and long-term, (Long-COVID) and calls for specific, personalized PC strategies relevant in a lockdown 
setting globally. Validated assessment tools should be applied remotely to flag up particular motor or 
NMS that require special attention, both in short- and long-term.
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1. The need for a unified palliative care pathway for 
PwP during the COVID-19 pandemic with 
implications for the future pandemics
The importance of palliative care (PC) throughout the course 
of Parkinson’s disease (PD) has now increasingly been recog-
nized. PC prioritizes quality of life (QoL) and focuses on pre-
vention and relief of physical, emotional and spiritual suffering 
through a multidisciplinary approach, and in a holistic manner, 
being ‘patient-centered’ rather than ‘disease-centered’ inter-
vention [1,2]. By contrast, traditional model of care for people 
with Parkinson’s (PwP), based on a patient-neurologist dyad,
present in most countries, may not be sufficient to tackle the 
burden of motor and non-motor symptoms (NMS), both key 
determinants of QoL in PD [3]. The emphasis on the palliative 
needs of PwP has gradually unfolded with the emergence of 
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV 
-2) pandemic, and its potential detrimental effect on PwP, 
particularly those at the advanced, complex phase of the 
condition [4–6].
Emerging evidence outlines that the societal and physical 
impacts of the ongoing COVID-19 pandemic might interact 
negatively with a range of motor and NMS, and particularly 
with frailty associated with the advanced stages of PD. These
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effects may be attributable to the COVID-19 pandemic both 
directly and indirectly and call for specific, personalized stra-
tegies relevant in a lockdown setting over the globe [7]. 
Furthermore, the development of such strategies may also 
allow for an intervention to be available for delivery and 
implementation, should there be a pandemic of a similar nat-
ure in the future [7].
Here, we propose a clinically orientated and rapidly deploy-
able, consensus-based, pragmatic palliative care approach for 
PwP relevant to the landscape of the ongoing COVID-19 pan-
demic and set a roadmap for future use globally. The pro-
posed approaches detailed here are based on personally
adopted strategies in several countries across different con-
tinents, as represented in the authorship of this paper.
2. Specific palliative care needs in PwP during the 
COVID-19 pandemic
As highlighted in Figure 1, two main principles form the 
foundation of the PC approach for PwP during the COVID-19 
pandemic: the improvement of QoL, and the prevention and 
relief of physical, emotional and spiritual suffering. Of note, 
unlike the traditional postulation that PC is only relevant at 
the late stage of PD, we advocate for implementation of PC 
strategies earlier in the course of PD, at its moderate stages – 
‘early integration of PC’. We propose that the enablers of these 
two principles can be mediated through the following 
interventions:
2.1. Clinical interventions to ensure adequate 
management of motor symptoms (worsening 
bradykinesia, akinesia and poor quality ‘off’ state) and 
prevention of deterioration
Available publications (a case study and several community- 
based studies) highlighted worsening of motor symptoms, 
particularly aggravation of bradykinesia and reduced mobility 
in PwP, particularly those at late stage and with associated 
frailty, during the COVID-19 pandemic [4,6]. Management stra-
tegies thus need to focus on preventing and counteracting 
the worsening of rigidity and tremor and decreasing mobility, 
considering the increased requirements for dopamine replace-
ment therapy (DRT) in a personalized manner. Improved 
motor status can also indirectly enhance the patients’ ability 
to combat an infection [7]. In frail, elderly PwP with an acute 
COVID-19 infection in a hospital environment, akinetic crisis
Article highlights
● Palliative care (PC) prioritizes quality of life (QoL) and focuses on the 
prevention and relief of physical, emotional and spiritual suffering 
through a multidisciplinary approach, and in a holistic manner; it is 
‘patient-centered’ rather than ‘disease-centered’
● The current COVID-19 pandemic might interact negatively with 
a range of motor and non-motor symptoms (NMS) people with 
Parkinson’s disease (PD, PwP) experience.
● Validated screening tools, such as the self-completed NMS 
Questionnaire (NMSQuest), should be applied remotely for staging 
of NMS burden and flagging up of particular NMS, while symptom- 
specific instruments may be used to further delineate and quantify 
the problem
● PC approaches for PwP during the COVID-19 pandemic should 
address the management of psychosocial and spiritual distress and 
anticipatory grief
● During the COVID-19 pandemic, shielding at home and restrictions of 
home care packages might enhance caregiver burden
● Advanced care planning (ACP) is necessary in order to meet patient’s 
care goal and avoid potentially unwanted interventions such as 
intubation, ventilation and intensive care unit admissions in the 
case of irreversible worsening; a clear plan regarding end-of-life 
decision-making process needs to be made on a case by case basis.
Figure 1. The possible enablers of patient-centered, holistic approach to palliative care for people with Parkinson’s during the COVID-19 pandemic. NMS – Non- 
motor symptoms, PwP – People with Parkinson’s.
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mimicking a neuroleptic malignant-like syndrome (NMS) or 
Parkinson hyperpyrexia syndrome might occur – this calls for 
urgent restoration of dopamine balance and supportive mea-
sures (e.g., hydration, antipyretics, non-oral use of DRT) [8].
2.2. Prevention and management of delirium
In elderly, frail PwP, COVID-19 infection itself possess a risk of 
delirium; personal protective equipment (PPE), limited cogni-
tive stimulation and mobility and restricted social interactions 
may act as further contributing factors. For example, due to 
restricted visiting policies, loss of access to face to face inter-
preters might aggravate confusion in PwP whose native lan-
guage differs from the one in the country they are residing in. 
In turn, delirium may lead to increased morbidity, prolonged 
hospital stays and increased mortality. Thus, systematic assess-
ment and early recognition of delirium are essential [9–11]. 
Proposed strategies for the prevention and management of 
delirium(both hypo- and hyperactive) in PwP affected by 
COVID-19 are summarized in Figure 2.
2.3. Management of non-motor symptoms
Current evidence suggests worsening of a range of NMS 
associated with COVID-19 infection, with a particularly 
severe impact on PwP at late, palliative stages of PD. 
These symptoms are listed in Figure 3. and range from 
neuropsychiatric issues to pain [4,5,12]. Worsening of NMS 
such as pain, anxiety and depression could also be an 
indirect consequence of the pandemic and related restric-
tions [13–15]. Of note, a detailed discussion on interventions 
for optimal treatment of particular NMS is beyond the scope 
of this paper; an International Parkinson and Movement 
Disorders Society Evidence-based Medicine (MDS-EBM) 
Task Force guidelines should be followed [16]. In addition, 
management of non-motor complications in a late stage PD 
has been extensively reviewed recently [17].
We advocate for the use of validated tools, such as the self- 
completed NMS Questionnaire (NMSQuest), which can be 
applied remotely and allows for time-efficient staging of 
NMS burden, while also flagging up particular NMS occurring 
as an integral part of ‘COVID-19 PD Syndrome’ that require
Figure 2. Prevention and management of delirium, both hypo- and hyperactive, in PwP affected by COVID-19. DRT – dopamine replacement therapy, ACB – 
Acetylcholine cognitive burden scale.
Figure 3. Worsening of particular non-motor symptoms in PwP during the COVID-19 pandemic. PwP – People with Parkisnon’s, NMS - Non-motor symptoms, 
NMSQuest – Non-motor Symptoms Questionnaire.
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special attention, both in short- and long-term [18–20]. Figure 
3. Once a specific NMS is identified using NMSQuest, symp-
tom-specific instruments may be used to further delineate and 
quantify the problem (e.g., MOCA in the case of cognitive 
deterioration) [21].
Some of the specific NMS of importance for PC are high-
lighted below.
● Fatigue: Fatigue has been identified as one of the 
NMS dominating the acute COVID-19 infection [4,5]. 
Several reports described a chronic post-viral fatigue 
syndrome after COVID-19 infection, marked by an over-
whelming sense of tiredness and lack of energy, that 
might possibly continue for a long time, now being 
recognized as an integral part of the ‘Long-COVID’ 
syndrome [22,23].
● Anxiety: Anxiety was at the forefront of symptoms 
reported in the initial case series by Antonini et al. 
and continues to be reported in PwP affected by 
COVID-19 [4]. In addition, anxiety, particularly in 
PwP at late stages of the disease, is a common con-
sequence of prolonged shielding, homestay and lack 
of exercise. Uncertainty related to, for example, the 
deployment of clinical staff to the frontline, which 
has led to restricted access to established care path-
ways for PwP in many countries, might be an addi-
tional contributing factor [4,5,13,15,24].
● Depression: During the COVID-19 pandemic, preva-
lence and severity of depression, as measured by 
Hospital Anxiety and Depression Scale (HADS) is higher 
among PwP than in healthy population [25]. Periods of 
acute depressive episodes have been witnessed in late 
stage PD, often coinciding with anxiety. Furthermore, 
mood disturbances (depression and anxiety) are one of 
the major aspects of the clinical expression of the 
‘Long-COVID’ syndrome [22].
● Pain: A substantial proportion of PwP affected by 
COVID-19 suffers from musculo-skeletal pain, while in 
those non-infected, worsening of pre-existing PD- 
related pain amid the ongoing COVID-19 pandemic 
has been reported [5,13,15]. Data capture from tele- 
health consultations for PwP during the lockdown in 
a UK center found significant worsening of pain in 
PwP, most likely attributable to social isolation and life-
style changes associated with shielding. 64% of PwP 
across all Hoehn and Yahr (HY) stages declared worsen-
ing of pain amid the ongoing COVID-19 pandemic. On 
the 11-point Numeric Rating Scale, patients scored the 
pain present at the time point of the assessment sig-
nificantly higher than the pain they were experiencing 
prior to the pandemic (7.64 ± 1.55 vs. 5.32 ± 2.88; 
p < 0,01) [26,27]. Figure 4.
● Sleep disturbances: In PwP, particularly those at later 
stages of the disease, pandemic-related social isolation 
and home confinement may adversely affect the quality 
of nighttime sleep. Importantly, worsening of pre-exist-
ing or a new onset of sleep disturbances might possibly 
further contribute to secondary worsening of motor and 
NMS [28]. Thus, addressing both primary and secondary 
insomnia, rapid eye movement sleep behavior disorders 
(RBD) and excessive daytime sleepiness should be an 
integral part of PC for PwP during the COVID-19 
pandemic.
● Cognitive impairment: COVID-19-related restrictions 
might possibly lead to a degree of a decline in cognitive 
performances in a proportion of PwP; possibly even 
causing the conversion from mild cognitive impairment 
to significant cognitive impairment in some patients at 
the late or palliative stage of PD [29]. Worryingly, wor-
sening of cognition has emerged as a symptom integral 
to the Long-COVID syndrome and may be specifically 
relevant for PwP Figure 5.
Figure 4. Worsening of PD-related pain during the COVID-19 pandemic – King’s experience. NRS – Numeric rating scale.
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3. Risk assessment for patients from ethnic 
minorities
Individuals from ethnic minorities have been affected by 
COVID-19 in a disproportionate manner, with higher mor-
tality and morbidity reported [7,30]. In British hospitals, 
COVID-19 mortality rate is 3.5 times higher in people of 
Black African descent, than in White patients [31]. Of note, 
in individuals with an ethnic minority background, PC inter-
ventions need to be tailored in accordance with the cul-
tural, religious and spiritual beliefs of the communities 
involved.
4. Outcome measures in palliative care for people 
with Parkinson’s
Patient centered PC outcome measures might aid the recogni-
tion of complex PC needs in PwP, beyond those related solely 
to physical symptoms.
Frequently used for general PC purposes, the Palliative 
Outcome Scale (POS) comprises two parts: a staff-completed 
and a patient-completed form, with 10 questions addressing 
physical, psychological, and spiritual domains of life within the 
remit of PC. An open section at the end of the scale provides 
the opportunity to list the main problems as an additional 
input. With an estimated completion time of less than 10 
minutes, this scale is brief and simple to administer [32]. 
Based on the POS, the IPOS-Neuro S8 was designed and 
validated specifically for individuals with progressive long- 
term neurological conditions, and could aid remote clinical 
assessments, although specific validation in PwP is 
awaited [33].
5. Addressing psychosocial and spiritual concerns 
and management of anticipatory grief
These issues are prevalent in PwP, similarly to many other 
patients of differing conditions. Spiritual care is an openness 
toward spiritual dimension and acknowledges both patients’ 
and caregivers’ resources and needs, while also being tolerant 
toward and accepting patients’ and caregivers’ wish not to 
discuss spiritual needs and concerns with healthcare providers 
[34–36]. Spiritual care in palliative care pays attention to spiri-
tuality via presence, empowerment, and bringing peace [37].
During the pandemic, the need to recommit to spiritual care as 
an essential component of whole-person PC may not have been 
fully respected in some settings. For instance, reduced ability to 
engage in one’s usual religious community has been a source of 
spiritual distress for many of our patients. Furthermore, there are 
also concerns about the future, spanning finances, personal 
appearance, identity and social relationships. Coping strategies, 
such as meditation and prayer, are important sources of strength 
for some PwP and might have important implications in the 
management of psychosocial and spiritual distress and anticipa-
tory grief [14,38]. Moreover, certain religious communities favor 
dying at home rather than in a hospice or hospital, while for 
others, visiting at death or washing the body after death is obli-
gatory. Where practicable, such requirements need to be accom-
modated in clinical pathways in order to mitigate further distress.
6. Advanced care planning
In the landscape of COVID-19 pandemic, advanced care plan-
ning (ACP) is necessary in order to meet patient’s care goals and 
avoid potentially unwanted interventions, such as intubation, 
ventilation and intensive care unit admissions in the case of
Figure 5. A flowchart addressing palliative and advanced care during COVID-19 pandemic tailored for people with Parkinson’s. PwP – People with Parkinson’s, HCP – 
Health Care Professional, NMS – Non-motor symptoms, NMSQ – NMS Questionnaire.
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irreversible worsening. Health-care professionals should review 
the ACP and discuss goals of care with PwP and their families 
during the routine consultations. If PwP contract COVID-19 and 
a hospital admission is necessary, the advance directive should 
accompany the patient [39]. In certain countries, ACP forms may 
include a free text area allowing clinicians to document patient’s 
and family’s expressed goals beyond a level of care designation.
7. End-of-life support
There has been a substantial variability in the reported mor-
tality rates among PwP affected by COVID-19. For example, in 
a dual center case series including hospitalized PD patients 
affected by COVID-19 (mean age 78.3 years, mean disease 
duration 12.7 years, mainly living in a nursing home), mortality 
rate was 40% [4]. Overall, mortality rate in elderly and frail PwP 
at late stages of PD appears to be high. For example, in 
another cohort-based study, mortality rate was as high as 
75% [40]. End of life support strategies based on PC approach 
in this subset of patients are therefore an imperative and 
currently an unmet need [13,41–44].
In addition, the COVID-19 pandemic might have an indirect 
effect on the mortality in PwP, and higher-than-expected rate 
of deaths in hospitalized PwP, irrespective of the infection 
with SARS-CoV-2, has been reported during this period [45].
However, notably, a ‘one size fits all’ approach toward 
rationing scarce resources such as ventilation is not appropri-
ate for all PD patients, as there is a broad consensus that long 
term outcome in PwP at HY stage 1 or 2 may be substantially 
different thanin those on HY stages 4 and 5. Thus, generic 
restrictions of ventilatory support, based solely on the PD 
diagnosis itself, as per current jurisdictions in certain countries, 
should not occur. Instead, a clear plan regarding end of life 
decision making process needs to be made on a case by case 
basis.
8. Caregiver support
Caregivers of PwP have considerable needs that need to be 
addressed through PC approach [38]. Of note, PwP’s motor 
and NMS are important predictor of caregivers’ QoL, which 
might therefore be diminished in the current pandemic [46]. In 
turn, higher caregiver burden is associated with adverse out-
comes, whereas presence of caregiver reduces spiritual distress 
and improves QoL in PwP [47,48]. During the ongoing COVID-19 
pandemic, shielding at home and restrictions of home care 
packages increase caregiver burden and there might be 
a need for a special task forces to tackles the issues caregivers 
might be facing (e.g. burn out, depression) and provide 
a platform for exchange [49]. Domestic stress might be aggra-
vated during periods of forced lockdown, adding an additional 
layer of stress for both caregivers and PwP [49]. Specific plans 
regarding support of caregivers in this situation are therefore 
important and should be integral to the overall PC strategy.
9. Vaccination
As of December 2020, vaccination is available against COVID- 
19 infection and late and particularly palliative stage PwP
should be considered a priority group to be vaccinated, 
along with their caregivers. Vaccination is identified as safe 
for PwP, and it does not interfere with a course of the disease. 
A similar strategy in relation to vaccination of vulnerable sub-
jects with multiple sclerosis has been proposed and can be 
adopted for palliative PD [50].
10. ‘Long-COVID’ in PD – implications for long-term 
care
The UK National Institute for Health and Care Excellence 
issued guidelines for management of long-term effects of 
COVID-19, referred as ‘Long-COVID’, and comprising signs 
and symptoms with an onset during or after the acute 
COVID-19 illness, persistent for more than 12 weeks, and not 
explained by an alternative underlaying diagnosis [51]. Wide 
range of symptoms may occur after an acute COVID-19 illness; 
they may fluctuate in severity and change their nature over 
time. In PwP, post-COVID-19 syndrome may interact nega-
tively with common NMS, unmasking fatigue, pain, sleep dis-
turbances and cognitive impairment and the evaluation of 
these aspects using validated screening tools is of paramount 
importance [52,53].
11. Expert opinion
Despite certain differences in opinions, PwP, particularly those 
with an advanced disease, are now widely recognized as 
a vulnerable group, with higher mortality rates of COVID-19 
being reported. Several studies suggest that elderly and frail 
PwP, or those with significant additional cardiovascular, meta-
bolic or respiratory comorbidities might be particularly vulner-
able and may thus fall under the umbrella of palliative care. 
The specific symptomatic approach to care for PwP during the 
ongoing COVID-19 pandemic needs to recognize and address 
a potential worsening of, or emergence of, specific PD fea-
tures, both motor and non-motor, as outlined in this paper. 
While the management of NMS such as fatigue, insomnia, 
anxiety and pain may be of a particular relevance in the 
short term, PwP affected by COVID-19 may potentially require 
further interventions for ‘Long-COVID’ related symptoms in 
the long run – namely, a personalized care approach might 
be required to tackle the cognitive decline, a common symp-
tom of the ‘Long-COVID’. A unified and personalized PC 
approach should seek to combine successful symptomatic 
relief of both motor and NMS, while also addressing issues 
related to end-of-life care in those critically ill, providing man-
agement of psycho-social concerns and spiritual beliefs, spe-
cifically if there is vaccine uptake hesitancy, and offer a clear 
pathway for caregiver support.
A composite, modern and time relevant PC strategy there-
fore needs to consider the above strands of care, as well as 
allow personalization considering the needs of each indivi-
dual, local pathways of care and clinical team preferences. 
The delivery of this care pathway becomes even more difficult 
during the pandemic, as face-to-face consultations or home 
visits may be restricted, or even impossible in many countries. 
The consequent effect on vulnerable patients and their care-
givers is considerable and ranges from mental health issues to
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worsening of physical symptoms. Therefore, a feasible care 
plan that can be delivered virtually and tackles the above 
concerns as far as possible needs to be developed and imple-
mented. Where the infrastructure permits to do so, ‘virtual 
clinics’ or consultations have been implemented. However, in 
some countries, this may not be possible and alternative 
routes must be sought via the use of smartphone apps or 
telephone contact to reach the ‘hard-to-reach’ population. For 
example, a hotline for stress relief for PwP and their families 
might serve as a front door approach, ameliorating a degree 
of initial stress and identifying those who may need urgent 
medical care. Aspects of NMS, such as anxiety, and loneliness 
can be helped by tele-health consultations while exercise 
strategies to help motor state, or support for speech, could 
be delivered through online platforms by trained therapists. 
The adjustments of the dopaminergic and other medication 
can be performed remotely to improve the motor and non- 
motor status of the patient, thus default helping the caregiver 
as well. The clinical decision making here might be aided by 
wearable sensors which allow for continuous remote monitor-
ing of symptoms. Specific screening tools, such as NMS 
Questionnaire (NMSQuest), POS, IPOS-Neuro S8,PDQ-8 or PD 
Sleep Scale (PDSS) can be administrated remotely to assess 
certain NMS and should be encouraged [18,54,55,32,33]. Only 
a concerted effort by key stakeholders, clinicians, allied health 
specialists, patients, caregivers and policymakers would make 
optimal palliative care delivery for the most vulnerable PD 
patients possible and prepare for future pandemics, should 
they arise.
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